APSR2026-221

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP09-004
P130
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1207003-46904-Poster_428831.pdf
Format: PDF Only
14. Respiratory Structure and Function
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Mark Mau Shin Poh * Tan Tock Seng Hospital Respiratory & Critical Care Medicine Singapore Singapore
Danqing Qi - Tan Tock Seng Hospital Respiratory & Critical Care Medicine Singapore Singapore
Geak Poh Tan - Tan Tock Seng Hospital Respiratory & Critical Care Medicine Singapore Singapore
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Mark Mau Shin
Poh
zzpohmark@hotmail.com
+6598211912
31-40
Singapore
Original Research
Clinical audit of nasal nitric oxide testing in a tertiary hospital in Singapore
Maximum 25 words
Abstract Content
Nasal nitric oxide (nNO) measurement is a non-invasive screening test for primary ciliary dyskinesia (PCD). While its clinical utility in children is well-established, data in adults remain limited. We aimed to study the prevalence, indications, and eventual diagnoses in adults referred for nNO testing
We conducted a single-centre retrospective study of consecutive referrals for nNO testing at Tan Tock Seng Hospital, between 2019 and 2025. Nasal NO was measured using the electrochemical NIOX VERO (NIOX, Sweden) device via tidal breathing method. Results in ppb were converted to nL/min by factor of 0.3. Corresponding clinical data of these patients was then extracted from electronic medical records, including demographics, comorbidities, spirometry readings, PICADAR scores and eventual diagnosis.
53 nNO tests in 51 patients were identified from 2019 to 2025. The three most common respiratory conditions were bronchiectasis (n=36, 77%), Asthma (n=16, 32%), prior recurrent pneumonias (n=11, 21%). Estimated testing prevalence of 0.6 tests per 100000 population, or 0.3% of[GT2.1] bronchiectasis cases. The mean (standard deviation) age was 58.1 (16.5); 40% were females, and 89% were ethnic Chinese. Median (range) PICADAR score was 0 (IQR: 0-1). The three most common respiratory conditions were bronchiectasis (n=36, 77%), Asthma (n=16, 32%), prior recurrent pneumonias (n=11, 21%). Eight cases (17%) had nNO <70nL/min; final diagnoses were bronchiectasis (n=5), diffuse panbronchiolitis (n=2), and unknown (n=1). Three patient underwent targeted genetic testing (two for suspected CF and one for suspected PCD). Only one case of variant of unknown significance for PCD was detected.
NNO test is rarely performed in adults. While nNO is a good test of exclusion, confirmatory genetic testing is rarely pursued when level is low. These findings highlight limited clinical uptake of nNO tests and suggests the need for clearer diagnostic pathways.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1207003-37089-D_373441.jpg
JPG or JPEG or PNG format ONLY
nasal nitric oxide, lung function, bronchiectasis
maximum 3 keywords and no abbreviations, separated by commas
 
305